EDGAR·FLOW

Silo Pharma, Inc. — Form 8-K

Filed November 6, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 71/100
What the filing says
Silo Pharma (market cap ~$5.3M) executed a private placement on November 5, 2026, selling up to $1.1 million aggregate of common shares and pre-funded warrants to accredited investors at $1.50 per share (warrant exercise price $0.0001). The offering includes registration rights and a waiver from H.C. Wainwright. Proceeds are for working capital; use restricted from debt repayment, redemptions, litigation settlement, and FCPA/OFAC violations.
Why this rating

Capital raise of $1.1M represents ~21% of $5.3M market cap—material for survival and operations. Immediate cash infusion aids liquidity. Pre-funded warrants create dilution and downward price pressure risk. Positive: working capital; Negative: significant shareholder dilution, hedging risk acknowledged in covenant.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.41 ▲ 6.01%
at our read · unknown
$1.33
+10 min · unknown
$1.46 ▲ 9.77%
+30 min · unknown
$1.48 ▲ 10.90%
+1 hr · unknown
$1.52 ▲ 14.66%
+4 hrs · unknown
$1.64 ▲ 23.08%

The stock had already moved -5.67% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ SILO · stock on Yahoo Finance ↗

See more from November 6, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.